Evaluating long-term cardiovascular risks after heart procedures
Residual CardioVascular Risk (RCVR) After Percutaneous Coronary Intervention: a Prospective Multicenter Study
CHA University · NCT06619353
This study is trying to see how leftover heart risks after a heart procedure affect the long-term health of people who had a PCI.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 20 Years to 90 Years |
| Sex | All |
| Sponsor | CHA University (other) |
| Locations | 1 site (Seongnam-si, Gyeonggi-do) |
| Trial ID | NCT06619353 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the long-term effects of residual cardiovascular risk on clinical outcomes in patients who have undergone percutaneous coronary intervention (PCI). It focuses on various risk factors, including thrombotic, metabolic, inflammatory, and procedural elements, assessed one month post-intervention. Participants will undergo artificial intelligence-based quantitative coronary analysis and comprehensive laboratory tests to evaluate these risks at one month and annually for three years. The primary goal is to determine how these residual risks impact long-term health outcomes.
Who should consider this trial
Good fit: Ideal candidates are patients who have recently undergone percutaneous coronary intervention and can provide informed consent.
Not a fit: Patients under 19 years of age, pregnant or breastfeeding women, and those with a recent history of malignancy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients undergoing PCI, potentially reducing long-term cardiovascular events.
How similar studies have performed: Other studies have explored residual cardiovascular risks, but this specific approach using artificial intelligence for quantitative analysis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who have undergone percutaneous coronary intervention. * Patients who have provided written informed consent. Exclusion Criteria: * Under 19 years of age. * Pregnant, breastfeeding, or women of childbearing age. * Currently has a malignancy or has a history of malignancy within the past 5 years. * Life expectancy of less than 5 years.
Where this trial is running
Seongnam-si, Gyeonggi-do
- CHA Bundang Medical Center — Seongnam-si, Gyeonggi-do, Korea, Republic of (RECRUITING)
Study contacts
- Principal investigator: Seung-Yul Lee, MD — CHA Bundang Medical Center
- Study coordinator: Hwa-In Kim
- Email: niawhz23@gmail.com
- Phone: 82-31-780-5858
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Coronary Artery Disease, Percutaneous Coronary Intervention